{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000007","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.960530+00:00","generated_at":"2026-06-05T19:31:47.862483+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted","bullets":["Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.","Q4 net loss $47.1M ($0.45 loss per share); adjusted EBITDA -$31.6M.","Active patients 3,755 (+9% YoY); prescriptions 1,564 (+14% YoY).","FDA accepted PMA for TTFields in NSCLC; enrollment completed in phase 3 TRIDENT trial.","Cash, cash equivalents and short-term investments $910.6M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000007","json":"https://secwatch.observer/filing/0001645113-24-000007.json","markdown":"https://secwatch.observer/filing/0001645113-24-000007.md","text":"https://secwatch.observer/filing/0001645113-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/nvcr-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:31:47.862483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7982f36232458c4eb3e97bf6879ed0d3aecaf1dc","claim":"NovoCure Ltd reported the fiscal year ended December 31, 2023 results: revenue $509.3 million.","evidence_excerpt":"Total net revenues for the year were $509.3 million, a decrease of 5% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$509.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c5cb831681a170a23c4849dbf56f51528860cffe","claim":"NovoCure Ltd reported the quarter ended December 31, 2023 results: revenue $133.8 million, net income Net loss for the quarter was $47.1 million, EPS loss per share of $0.45.","evidence_excerpt":"Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$133.8 million"},{"label":"Net income","value":"Net loss for the quarter was $47.1 million"},{"label":"EPS","value":"loss per share of $0.45"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}